Supernus Pharmaceuticals, Inc. - Common Stock (SUPN)
38.85
-0.63 (-1.60%)
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of central nervous system disorders, particularly epilepsy and attention deficit hyperactivity disorder (ADHD)
The company leverages its proprietary drug formulation technologies to create specialized medications that enhance patient outcomes. With a commitment to addressing unmet medical needs, Supernus actively engages in research and development, aiming to expand its product offerings and provide effective treatment solutions for patients suffering from these challenging conditions.
Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in Qelbree prescriptions during back-to-school season, with a revised peak sales target of $400 million.
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.
Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product quality and infusion device master file. No clinical safety or efficacy issues identified.
Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to Botox and similar injections.
